Drug Trial Radar · NCT07287397
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Oct 15, 2027
Study completion Oct 15, 2027
Sponsor
- Lead sponsor
- Vector Y TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
VTx-002Genetic
An investigational gene therapy targeting a specific protein.
Preventative (Prophylactic) Medication - Corticosteroids: MethylprednisoloneDrug
To reduce the risk of reactions caused by the study treatment, steroid medicines will be given in advance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: over 5 years
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
- The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: At month 6 and month 12
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
St Joseph's Hospital and medical Center - Barrow Neurological Institute
Phoenix, Arizona · Not yet recruiting
University of California San Diego Medical Center
San Diego, California · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital
Boston, Massachusetts · Recruiting
The Eleanor & Lou Gehrig ALS Center
New York, New York · Not yet recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
UMC Utrecht
Utrecht, Netherlands · Recruiting
Royal Hallamshire Hospital
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.